Ivo Meinhold-Heerlein

Prof. Dr. Ivo Meinhold-Heerlein

Department of Gynecology and Obstetrics, Medical Faculty, Justus-Liebig-University Giessen, Klinikstr. 33, 35392 Giessen, Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AMAmaia Eleonora Maennling
Amaia Eleonora Maennling
MTMehmet Kemal Tur
Mehmet Kemal Tur
MNMarcus Niebert
Marcus Niebert
TKTorsten Klockenbring
Torsten Klockenbring
FZFelix Zeppernick
Felix Zeppernick
Ahmad Fawzi HussainAhmad Fawzi Hussain
Ahmad Fawzi Hussain
The epidermal growth factor receptor (EGFR) family contains four transmembrane tyrosine kinases (EGFR1/ErbB1, Her2/ErbB2, Her3/ErbB3 and Her4/ErbB4) and 13 secreted polypeptide ligands. EGFRs are overexpressed in many solid tumors, including breast, pancreas, head-and-neck, prostate, ovarian, renal, colon, and non-small-cell lung cancer. Such overexpression produces strong stimulation of downstream signaling pathways, which induce cell growth, cell differentiation, cell cycle progression, angiogenesis, cell motility and blocking of apoptosis.The high expression and/or functional activation of EGFRs correlates with the pathogenesis and progression of several cancers, which make them attractive targets for both diagnosis and therapy. Several approaches have been developed to target these receptors and/or the EGFR modulated effects in cancer cells. Most approaches include the development of anti-EGFRs antibodies and/or small-molecule EGFR inhibitors. This review presents the state-of-the-art and future prospects of targeting EGFRs to treat breast cancer.

Verified
Journal Article
Open access
PDF file
WSWenjie Sheng
Wenjie Sheng
CZChaoyu zhang
Chaoyu zhang
TM MohiuddinTM Mohiuddin
TM Mohiuddin
MAMarwah Al-Rawe
Marwah Al-Rawe
FZFelix Zeppernick
Felix Zeppernick
Ahmad Fawzi HussainAhmad Fawzi Hussain
Ahmad Fawzi Hussain
Traditional immunohistochemistry (IHC) has already become an essential method of diagnosis and therapy in cancer management. However, this antibody-based technique is limited to detecting a single marker per tissue section. Since immunotherapy has revolutionized the antineoplastic therapy, developing new immunohistochemistry strategies to detect multiple markers simultaneously to better understand tumor environment and predict or assess response to immunotherapy is necessary and urgent. Multiplex immunohistochemistry (mIHC)/multiplex immunofluorescence (mIF), such as multiplex chromogenic IHC and multiplex fluorescent immunohistochemistry (mfIHC), is a new and emerging technology to label multiple biomarkers in a single pathological section. The mfIHC shows a higher performance in cancer immunotherapy. This review summarizes the technologies, which are applied for mfIHC, and discusses how they are employed for immunotherapy research.

Verified
Journal Article
Open access
PDF file
Lutz KonradLutz Konrad
Lutz Konrad
RDRaimund Dietze
Raimund Dietze
MRMuhammad Assad Riaz
Muhammad Assad Riaz
GSGeorgios Scheiner-Bobis
Georgios Scheiner-Bobis
JBJudith Behnke
Judith Behnke
Ivo Meinhold-HeerleinIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
Epithelial–mesenchymal transition (EMT) is an important process of cell remodeling characterized by the gradual loss of the epithelial phenotype and progressive gain of a mesenchymal phenotype. EMT is not an all-or-nothing process, but instead a transition of epithelial to mesenchymal cells with intermediate cell states. Recently, EMT was described in endometriosis, and many EMT-specific pathways like Twist, Snail, Slug, Zinc finger E-box-binding homeobox 1/2 (ZEB1/2), E/N-cadherin, keratins, and claudins are involved. However, as pointed out in this review, a comparison of the eutopic endometrium of women with and without endometriosis yielded only subtle changes of these EMT markers. Furthermore, only very few alterations in cell–cell contacts could be found but without changes in the epithelial phenotype. This suggests only a partial EMT which is not a prerequisite for the detachment of endometrial cells and, thus, not critical for the first step(s) in the pathogenesis of endometriosis. In contrast, the majority of changes in the EMT-related marker expression were found in the ectopic endometrium, especially in the three endometriotic entities, ovarian, peritoneal, and deep infiltrating endometriosis (DIE), compared with the eutopic endometrium. In this review, we examine the most important EMT pathways described in endometriosis and propose that partial EMT might result from the interaction of endometrial implants with their surrounding microenvironment.

Verified
Journal Article
Open access
PDF file
TM MohiuddinTM Mohiuddin
TM Mohiuddin
CZChaoyu zhang
Chaoyu zhang
WSWenjie Sheng
Wenjie Sheng
MAMarwah Al-Rawe
Marwah Al-Rawe
FZFelix Zeppernick
Felix Zeppernick
Ahmad Fawzi HussainAhmad Fawzi Hussain
Ahmad Fawzi Hussain
Near infrared photoimmunotherapy (NIR-PIT) is a newly developed molecular targeted cancer treatment, which selectively kills cancer cells or immune-regulatory cells and induces therapeutic host immune responses by administrating a cancer targeting moiety conjugated with IRdye700. The local exposure to near-infrared (NIR) light causes a photo-induced ligand release reaction, which causes damage to the target cell, resulting in immunogenic cell death (ICD) with little or no side effect to the surrounding normal cells. Moreover, NIR-PIT can generate an immune response in distant metastases and inhibit further cancer attack by combing cancer cells targeting NIR-PIT and immune regulatory cells targeting NIR-PIT or other cancer treatment modalities. Several recent improvements in NIR-PIT have been explored such as catheter-driven NIR light delivery, real-time monitoring of cancer, and the development of new target molecule, leading to NIR-PIT being considered as a promising cancer therapy. In this review, we discuss the progress of NIR-PIT, their mechanism and design strategies for cancer treatment. Furthermore, the overall possible targeting molecules for NIR-PIT with their application for cancer treatment are briefly summarised.

8 April 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ahmad Fawzi HussainAhmad Fawzi Hussain
Ahmad Fawzi Hussain
AGArmin Grimm
Armin Grimm
WSWenjie Sheng
Wenjie Sheng
CZChaoyu zhang
Chaoyu zhang
MAMarwah Al-Rawe
Marwah Al-Rawe
Ivo Meinhold-HeerleinIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
In the last few decades, antibody-based diagnostic and therapeutic applications have been well established in medicine and have revolutionized cancer managements by improving tumor detection and treatment. Antibodies are unique medical elements due to their powerful properties of being able to recognize specific antigens and their therapeutic mechanisms such as blocking specific pathways, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxicity. Furthermore, modification techniques have paved the way for improving antibody properties and to develop new classes of antibody-conjugate-based diagnostic and therapeutic agents. These techniques allow arming antibodies with various effector molecules. However, these techniques are utilizing the most frequently used amino acid residues for bioconjugation, such as cysteine and lysine. These bioconjugation approaches generate heterogeneous products with different functional and safety profiles. This is mainly due to the abundance of lysine and cysteine side chains. To overcome these limitations, different site-direct conjugation methods have been applied to arm the antibodies with therapeutic or diagnostics molecules to generate unified antibody conjugates with tailored properties. This review summarizes some of the enzyme-based site-specific conjugation approaches.

19 September 2025 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Open access
RLRosa Lakabi
Rosa Lakabi
SHSebastian Harth
Sebastian Harth
Ivo Meinhold-HeerleinIvo Meinhold-Heerlein
Ivo Meinhold-Heerlein
AOAlisha V. Olsthoorn
Alisha V. Olsthoorn
MMMalcolm G. Munro
Malcolm G. Munro
AMAlly Murji
Ally Murji
Uterine fibroids, or leiomyomas, are benign uterine tumors with a lifetime prevalence of approximately 75%. While only a minority become symptomatic, their impact on quality of life remains profound owing to heavy menstrual bleeding, bulk symptoms, and reproductive dysfunction. Interestingly, fibroids are not reliably diagnosed on physical examination, nor can their impact be predicted through palpation. Consequently, the diagnosis and phenotypic categorization of uterine fibroids relies primarily on imaging to guide subsequent clinical management. Ultrasound should be the first‐line diagnostic modality, and magnetic resonance imaging should be reserved for complex cases and/or surgical planning. Adherence to standardized structured reporting across imaging modalities is critical to improve diagnostic accuracy, differentiate fibroids from conditions such as adenomyosis or malignancies, predict therapeutic responses, and plan surgical interventions. Imaging reports should follow the FIGO classification system for uterine fibroids, to enable a standardized description of their relationship to the endometrium, myometrium, and uterine serosa.